Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BFRINASDAQ:OBSVNASDAQ:PMCBNASDAQ:SCNI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRIBiofrontera$0.70-4.1%$0.86$0.65▼$2.22$6.44M0.36915,767 shs65,998 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs217 shsPMCBPharmaCyte Biotech$1.24$1.43$1.03▼$2.42$8.51M-0.5321,568 shs2,797 shsSCNIScinai Immunotherapeutics$2.64+3.5%$2.85$1.90▼$8.92$2.47M2.68279,933 shs118,613 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRIBiofrontera-9.89%-12.59%-10.22%-30.49%-57.81%OBSVObsEva0.00%0.00%0.00%0.00%-60.00%PMCBPharmaCyte Biotech-3.88%+8.30%-6.06%-23.27%-41.51%SCNIScinai Immunotherapeutics+6.31%+21.40%-6.79%-26.06%-41.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFRIBiofrontera2.9049 of 5 stars3.54.00.00.03.30.01.3OBSVObsEvaN/AN/AN/AN/AN/AN/AN/AN/APMCBPharmaCyte Biotech1.6261 of 5 stars0.03.00.00.03.30.81.9SCNIScinai Immunotherapeutics1.5334 of 5 stars0.05.00.00.03.02.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRIBiofrontera 3.00Buy$7.00900.00% UpsideOBSVObsEva 0.00N/AN/AN/APMCBPharmaCyte Biotech 0.00N/AN/AN/ASCNIScinai Immunotherapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRIBiofrontera$37.32M0.17N/AN/A$3.16 per share0.22OBSVObsEva$20.11M0.00N/AN/A$0.41 per share0.00PMCBPharmaCyte BiotechN/AN/AN/AN/A$3.27 per shareN/ASCNIScinai Immunotherapeutics$452K5.46N/AN/A($9.84) per share-0.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRIBiofrontera-$20.13M-$2.26N/AN/AN/A-36.31%-565.73%-96.64%5/13/2025 (Estimated)OBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/APMCBPharmaCyte Biotech$330K$0.742.34∞N/AN/A0.76%0.45%N/ASCNIScinai Immunotherapeutics-$6.50M-$239.17N/A∞N/AN/AN/A-30.48%5/21/2025 (Estimated)Latest SCNI, OBSV, PMCB, and BFRI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025BFRIBiofrontera-$0.14N/AN/AN/A$10.55 millionN/A3/17/2025Q3 2025PMCBPharmaCyte BiotechN/A-$0.10N/A-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRIBiofronteraN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/APMCBPharmaCyte BiotechN/AN/AN/AN/AN/ASCNIScinai ImmunotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRIBiofronteraN/A1.530.94OBSVObsEvaN/A0.610.61PMCBPharmaCyte BiotechN/A4.474.47SCNIScinai Immunotherapeutics0.061.161.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRIBiofrontera10.08%OBSVObsEva17.52%PMCBPharmaCyte Biotech34.24%SCNIScinai Immunotherapeutics58.41%Insider OwnershipCompanyInsider OwnershipBFRIBiofrontera0.21%OBSVObsEva14.40%PMCBPharmaCyte Biotech10.20%SCNIScinai Immunotherapeutics60.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFRIBiofrontera709.21 million7.73 millionNo DataOBSVObsEva5077.97 million66.74 millionNot OptionablePMCBPharmaCyte Biotech46.86 million6.90 millionOptionableSCNIScinai Immunotherapeutics20934,000334,000Not OptionableSCNI, OBSV, PMCB, and BFRI HeadlinesRecent News About These CompaniesScinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological ConditionsMarch 27, 2025 | prnewswire.comScinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025March 17, 2025 | prnewswire.comSCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENTMarch 5, 2025 | prnewswire.comScinai Immunotherapeutics Ltd. (SCNI)January 28, 2025 | ca.finance.yahoo.comScinai Immunotherapeutics (NASDAQ: SCNI) to Engage Investors at January ConferencesJanuary 7, 2025 | theglobeandmail.comScinai to Connect with Investors and Pharma Leaders at Upcoming Key US ConferencesJanuary 6, 2025 | prnewswire.comScinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.December 16, 2024 | prnewswire.comProf. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory BoardDecember 5, 2024 | prnewswire.comScinai Immunotherapeutics (NASDAQ: SCNI) Welcomes Dr. Jonathan Sadeh to Scientific Advisory BoardDecember 3, 2024 | theglobeandmail.comThere Are Some Reasons To Suggest That Scinai Immunotherapeutics' (NASDAQ:SCNI) Earnings Are A Poor Reflection Of ProfitabilityNovember 29, 2024 | uk.finance.yahoo.comDr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory BoardNovember 27, 2024 | prnewswire.comScinai Immunotherapeutics Reports Financial Turnaround and GrowthNovember 26, 2024 | markets.businessinsider.comScinai Immunotherapeutics Gains Shareholder ConfidenceNovember 23, 2024 | markets.businessinsider.comScinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 millionNovember 22, 2024 | prnewswire.comScinai Immunotherapeutics (NASDAQ: SCNI) to Spotlight I&I Pipeline, CDMO Services at BIO-Europe 2024October 31, 2024 | theglobeandmail.comScinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024October 31, 2024 | prnewswire.comScinai Immunotherapeutics (NASDAQ:SCNI) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comScinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH AntibodiesSeptember 16, 2024 | prnewswire.comScinai Immunotherapeutics (NASDAQ: SCNI) CEO Featured on Latest Episode of BioMedWire PodcastSeptember 11, 2024 | theglobeandmail.comBioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) CEO Featured Guest on Latest Episode of BioMedWire PodcastSeptember 10, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSCNI, OBSV, PMCB, and BFRI Company DescriptionsBiofrontera NASDAQ:BFRI$0.70 -0.03 (-4.10%) As of 03:55 PM EasternBiofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.ObsEva NASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.PharmaCyte Biotech NASDAQ:PMCB$1.24 0.00 (0.00%) As of 04:00 PM EasternPharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.Scinai Immunotherapeutics NASDAQ:SCNI$2.64 +0.09 (+3.53%) As of 03:33 PM EasternScinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
